FLUOXETINE HYDROCHLORIDE (fluoxetine hcl) by Lavipharm is unknown, it is presumed to be linked to its inhibition of cns neuronal uptake of serotonin. First approved in 2011.
Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
Fluoxetine HCl is an oral tablet formulation of fluoxetine, a selective serotonin reuptake inhibitor (SSRI) approved in 2011 by NDA. It is presumed to work by inhibiting CNS neuronal uptake of serotonin, though the exact mechanism remains not fully elucidated. Fluoxetine treats depression and related psychiatric conditions in adult and pediatric patients.
Product is at peak lifecycle maturity with established market presence; commercial teams are focused on defending market share against 30% competitive pressure rather than growth initiatives.
unknown, it is presumed to be linked to its inhibition of CNS neuronal uptake of serotonin.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Bioequivalence Study of Fluoxetine Hydrochloride Delayed-Release Capsules, 90 mg of Dr. Reddy's Under Fasting Condition
Bioequivalence Study of Fluoxetine Hydrochloride Delayed-Release Capsules 90 mg of Dr. Reddy's Under Fed Condition
90 mg Fluoxetine Hydrochloride Capsules Under Non-Fasting Conditions
90 mg Fluoxetine Hydrochloride Capsules Under Fasting Conditions
To Demonstrate the Relative Bioavailability of Fluoxetine Hydrochloride Capsules, 40 mg
Worked on FLUOXETINE HYDROCHLORIDE at Lavipharm? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on fluoxetine HCl offers exposure to mature product management, generic competition dynamics, and defensive commercial strategy in a therapeutic area with large patient populations. Roles emphasize market maintenance, physician education, and cost-of-goods optimization rather than innovation or launch excitement.